# Integrum > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/integrum). ## Overview Integrum is a Swedish medical technology company focused on osseointegration systems that connect prosthetic limbs directly to the skeleton. Its core offering is the OPRA Implant System, supported by surgical procedures, implant components, and related devices used through a network of specialist clinics and Centers of Excellence, with the US as its main market and additional activity in Europe and other international markets. ## Products & services • OPRA Implant System for bone-anchored prosthetics • S1 and S2 surgical procedures • Axor II safety coupling and related components • Patient portal and care-flow support tools • Training and clinical support for partner clinics - **OPRA Implant System** (55%) — Implant-based osseointegration system used to attach prosthetic limbs directly to bone. - **Surgical procedures** (25%) — First- and second-stage procedures performed by specialist surgeons to implant and complete the system. - **Axor II and related components** (15%) — Safety coupling and accessory components used with the implant system and prosthetics. - **Clinical support and training** (5%) — Education, onboarding, and support services for clinics and partner hospitals. - OPRA Implant System for bone-anchored prosthetics - S1 and S2 surgical procedures - Axor II safety coupling and related components - Patient portal and care-flow support tools - Training and clinical support for partner clinics ## Customers Integrum sells primarily to specialist hospitals, orthopedic surgeons, and rehabilitation-focused clinics that treat amputees and complex prosthetic patients. The company also serves patients indirectly through its clinical partners, since the treatment pathway depends on surgeon adoption, center-of-excellence workflows, and follow-up care. Demand is driven by providers seeking advanced prosthetic solutions and by patients who need improved mobility and long-term function. - **Specialist hospitals** (primary) — Buy the implant system and procedures for advanced amputee reconstruction and prosthetic attachment. - **Orthopedic surgeons** (primary) — Adopt the OPRA system and perform S1/S2 procedures as part of their surgical practice. - **Rehabilitation centers** (secondary) — Support patient evaluation, recovery, and long-term functional follow-up. - **Centers of Excellence** (primary) — Serve as referral and treatment hubs for complex osseointegration cases. - **Patients with limb loss** (secondary) — End users of the system, reached through hospitals and specialist clinics. - Specialist hospitals performing osseointegration surgeries - Orthopedic surgeons and surgical teams - Rehabilitation centers treating amputees - Centers of Excellence managing complex patient pathways - Patients accessing the system through clinical referrals ## Geography Integrum is headquartered in Mölndal, Sweden, and operates through a Swedish parent company with a US subsidiary and international commercial activity. The US is the largest market disclosed in the reports, while Rest of the World includes priority markets such as the DACH region, Ukraine, and Israel. Geography matters because the business depends on local surgical adoption, clinic partnerships, reimbursement conditions, and the pace of market access in each country. - **US** (81%) — Based on disclosed revenue by market in Q1 2025/26. - **Rest of the World** (19%) — Includes international markets outside the US; specific country mix not fully disclosed. - Headquartered in Mölndal, Sweden - US is the largest disclosed revenue market - Rest of World includes DACH, Ukraine, and Israel - Commercial activity depends on local clinic adoption - Market access and reimbursement vary by country ## Strategy Integrum’s strategy centers on expanding the commercial reach of the OPRA Implant System by concentrating on Centers of Excellence and improving the patient pathway from referral to surgery. The company is also building local market presence in priority regions, strengthening digital tools, and supporting surgeon education to improve conversion and shorten lead times. These actions are intended to make adoption more scalable while preserving the specialist nature of the treatment model. - **Concentrate on Centers of Excellence** (short-term) — Specialist hubs improve procedure volume, referral quality, and clinical credibility. - **Improve digital patient flow** (short-term) — Better intake and follow-up can shorten lead times and improve conversion to surgery. - **Expand in priority international markets** (medium-term) — Broader geographic reach reduces dependence on one market and supports growth. - **Strengthen surgeon training and clinical support** (medium-term) — Adoption depends on surgeon familiarity, procedure quality, and partner confidence. - Focus on Centers of Excellence to deepen surgical adoption - Improve patient flow with digital portal and follow-up tools - Expand commercial presence in priority international markets - Strengthen surgeon training and clinical collaboration - Build a more scalable operating model for osseointegration ## Risks Integrum’s business depends on surgeon adoption, reimbursement, and the pace at which clinics move from interest to active procedures, which can make revenue lumpy and market-specific. The company also faces operational and regulatory risks tied to product quality, certifications, suppliers, foreign exchange, and the execution of a specialized medical procedure model. Because a large share of activity is concentrated in the US and in a limited number of centers, changes in clinical demand or market access can have an outsized effect. - **Dependence on surgeon and clinic adoption** [high] — The system requires specialist training and clinical acceptance before procedures scale. - **Geographic concentration in the US** [high] — A large share of revenue comes from one market, making results sensitive to local demand and reimbursement. - **Regulatory and certification risk** [medium] — Medical device commercialization depends on permits, certifications, and compliance. - **Supplier and product quality risk** [medium] — Specialized implants and components must meet strict quality standards to avoid disruption or recalls. - **Foreign exchange risk** [medium] — The company reports in SEK but earns revenue in multiple currencies, creating translation and transaction effects. - Revenue depends on surgeon adoption and clinic conversion rates - US concentration creates exposure to one market and reimbursement - Regulatory approvals and certifications can delay commercialization - Product quality or supplier issues could disrupt procedures - FX movements affect reported results across Sweden, US, and RoW ## Accounting Integrum’s reporting is affected by judgment around capitalized development costs, which can materially influence asset values and operating expenses. Revenue is also exposed to timing effects because the OPRA model involves staged procedures, so quarterly comparisons can shift with the mix of S1, S2, and component sales. In addition, IFRS 16 lease accounting, foreign-currency translation, and impairment testing of development assets are important areas for investors to monitor. - **Capitalized development expenditures** — Affects intangible assets, operating expenses, and impairment risk - **Revenue timing across staged procedures** — Can create quarter-to-quarter volatility in reported sales - **IFRS 16 leases** — Changes lease liabilities, depreciation, and interest expense - **Foreign exchange translation** — Can move equity and other comprehensive income - **Impairment testing** — Potential write-downs if expected cash flows weaken - Capitalized development costs require judgment on future benefit - Staged S1/S2 procedures can shift revenue timing between quarters - IFRS 16 lease accounting affects liabilities and operating costs - Foreign-currency translation affects reported equity and earnings - Impairment testing of development assets can change asset values --- *Last updated: 2026-08-11T04:04:53.480859+00:00*